PD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma

Sanjal H. Desai; Alison J. Moskowitz; Reid W. Merryman; Harsh Shah; Levi D. Pederson; Susan M. Geyer; Nivetha Ganesan; Tiffany Chang; Tamer Othman; Ayo S. Falade; Gunjan L. Shah; Urshila Durani; Nuttavut Sumransub; Lay She Ng; Kelsey Baron; Shin Yeu Ong; Kevin Yoon; Stephen M. Ansell; Philippe Armand; Siddharth Iyengar; Ivana Micallef; Robert Stuver; Alex F. Herrera; Matthew Mei

doi:10.1182/blood.2025030151

PD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma

Sanjal H. Desai
, Alison J. Moskowitz
, Reid W. Merryman
, Harsh Shah
, Levi D. Pederson
, Susan M. Geyer
, Nivetha Ganesan
, Tiffany Chang
, Tamer Othman
, Ayo S. Falade
, Gunjan L. Shah
, Urshila Durani
, Nuttavut Sumransub
, Lay She Ng
, Kelsey Baron
, Shin Yeu Ong
, Kevin Yoon
, Stephen M. Ansell
, Philippe Armand
, Siddharth Iyengar

Ivana Micallef, Robert Stuver, Alex F. Herrera, Matthew Mei

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

A significant minority of patients with advanced-stage Hodgkin lymphoma (HL) will relapse after frontline therapy, and some will have primary refractory disease. In a retrospective study of almost 1300 patients, Desai et al report that programmed death protein 1 inhibitor (PD-1i)–based salvage regimens prior to autologous transplantation are associated with improved progression-free survival compared to regimens based on chemotherapy or brentuximab vedotin, independent of potential confounders such as pretransplant remission state. These data reinforce the findings of small studies and make the case for incorporation of PD-1i in salvage for patients not previously treated with these agents in first-line therapy.

Original language	English (US)
Pages (from-to)	1125-1134
Number of pages	10
Journal	Blood
Volume	147
Issue number	10
DOIs	https://doi.org/10.1182/blood.2025030151
State	Published - Mar 5 2026

Bibliographical note

Publisher Copyright:
© 2026 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1182/blood.2025030151

Find It

Find It at U of M Libraries

Cite this

Desai, S. H., Moskowitz, A. J., Merryman, R. W., Shah, H., Pederson, L. D., Geyer, S. M., Ganesan, N., Chang, T., Othman, T., Falade, A. S., Shah, G. L., Durani, U., Sumransub, N., Ng, L. S., Baron, K., Ong, S. Y., Yoon, K., Ansell, S. M., Armand, P., ... Mei, M. (2026). PD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma. Blood, 147(10), 1125-1134. https://doi.org/10.1182/blood.2025030151

Desai, SH, Moskowitz, AJ, Merryman, RW, Shah, H, Pederson, LD, Geyer, SM, Ganesan, N, Chang, T, Othman, T, Falade, AS, Shah, GL, Durani, U, Sumransub, N, Ng, LS, Baron, K, Ong, SY, Yoon, K, Ansell, SM, Armand, P, Iyengar, S, Micallef, I, Stuver, R, Herrera, AF & Mei, M 2026, 'PD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma', Blood, vol. 147, no. 10, pp. 1125-1134. https://doi.org/10.1182/blood.2025030151

@article{f1f872cf1c19439998bba3e0b0d8721e,

title = "PD-1{\textendash}based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma",

abstract = "A significant minority of patients with advanced-stage Hodgkin lymphoma (HL) will relapse after frontline therapy, and some will have primary refractory disease. In a retrospective study of almost 1300 patients, Desai et al report that programmed death protein 1 inhibitor (PD-1i){\textendash}based salvage regimens prior to autologous transplantation are associated with improved progression-free survival compared to regimens based on chemotherapy or brentuximab vedotin, independent of potential confounders such as pretransplant remission state. These data reinforce the findings of small studies and make the case for incorporation of PD-1i in salvage for patients not previously treated with these agents in first-line therapy.",

author = "Desai, \{Sanjal H.\} and Moskowitz, \{Alison J.\} and Merryman, \{Reid W.\} and Harsh Shah and Pederson, \{Levi D.\} and Geyer, \{Susan M.\} and Nivetha Ganesan and Tiffany Chang and Tamer Othman and Falade, \{Ayo S.\} and Shah, \{Gunjan L.\} and Urshila Durani and Nuttavut Sumransub and Ng, \{Lay She\} and Kelsey Baron and Ong, \{Shin Yeu\} and Kevin Yoon and Ansell, \{Stephen M.\} and Philippe Armand and Siddharth Iyengar and Ivana Micallef and Robert Stuver and Herrera, \{Alex F.\} and Matthew Mei",

note = "Publisher Copyright: {\textcopyright} 2026 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.",

year = "2026",

month = mar,

day = "5",

doi = "10.1182/blood.2025030151",

language = "English (US)",

volume = "147",

pages = "1125--1134",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "10",

}

TY - JOUR

T1 - PD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma

AU - Desai, Sanjal H.

AU - Moskowitz, Alison J.

AU - Merryman, Reid W.

AU - Shah, Harsh

AU - Pederson, Levi D.

AU - Geyer, Susan M.

AU - Ganesan, Nivetha

AU - Chang, Tiffany

AU - Othman, Tamer

AU - Falade, Ayo S.

AU - Shah, Gunjan L.

AU - Durani, Urshila

AU - Sumransub, Nuttavut

AU - Ng, Lay She

AU - Baron, Kelsey

AU - Ong, Shin Yeu

AU - Yoon, Kevin

AU - Ansell, Stephen M.

AU - Armand, Philippe

AU - Iyengar, Siddharth

AU - Micallef, Ivana

AU - Stuver, Robert

AU - Herrera, Alex F.

AU - Mei, Matthew

PY - 2026/3/5

Y1 - 2026/3/5

N2 - A significant minority of patients with advanced-stage Hodgkin lymphoma (HL) will relapse after frontline therapy, and some will have primary refractory disease. In a retrospective study of almost 1300 patients, Desai et al report that programmed death protein 1 inhibitor (PD-1i)–based salvage regimens prior to autologous transplantation are associated with improved progression-free survival compared to regimens based on chemotherapy or brentuximab vedotin, independent of potential confounders such as pretransplant remission state. These data reinforce the findings of small studies and make the case for incorporation of PD-1i in salvage for patients not previously treated with these agents in first-line therapy.

AB - A significant minority of patients with advanced-stage Hodgkin lymphoma (HL) will relapse after frontline therapy, and some will have primary refractory disease. In a retrospective study of almost 1300 patients, Desai et al report that programmed death protein 1 inhibitor (PD-1i)–based salvage regimens prior to autologous transplantation are associated with improved progression-free survival compared to regimens based on chemotherapy or brentuximab vedotin, independent of potential confounders such as pretransplant remission state. These data reinforce the findings of small studies and make the case for incorporation of PD-1i in salvage for patients not previously treated with these agents in first-line therapy.

UR - https://www.scopus.com/pages/publications/105032210348

UR - https://www.scopus.com/pages/publications/105032210348#tab=citedBy

U2 - 10.1182/blood.2025030151

DO - 10.1182/blood.2025030151

M3 - Article

C2 - 41405496

AN - SCOPUS:105032210348

SN - 0006-4971

VL - 147

SP - 1125

EP - 1134

JO - Blood

JF - Blood

IS - 10

ER -

PD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this